Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$208 Mln
Revenue (TTM)
$7 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
--
EV/EBITDA
1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
26,612,100
CFO
$-1,805.09 Mln
EBITDA
$-1,648.80 Mln
Net Profit
$-1,873.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
| 11.7 | 16.5 | -0.5 | -- | 165.4 | 3.4 | -- |
|
BSE Sensex*
| 4.7 | 4.3 | 7.8 | 10.7 | 15.8 | 22.1 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
| -69.7 | 6.0 | -30.8 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
|
7.9 | 207.6 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.4 |
| 2.3 | 3.6 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 | |
| 0.3 | 4.1 | 7.5 | -9.0 | -144,731.8 | -0.3 | -- | 0.7 | |
| 0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 | |
| 0.6 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 | |
| 2.3 | 16.2 | 2.9 | -8.4 | -181.0 | -- | -- | 63.9 | |
| 1.3 | 208.8 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 2.0 | |
| 0.5 | 16.8 | 0.0 | -0.9 | -- | -11.2 | 5.7 | 1.8 | |
| 196.8 | 12,755.3 | 16,084.1 | 1,196.9 | 10.9 | 17.4 | 11.1 | 1.9 | |
| 0.9 | 4.1 | 0.0 | -3.3 | -- | -109.8 | -- | 1.2 |
ContextLogic Inc. does not have significant operations. It focuses on identifying, evaluating, and executing strategic opportunities. Previously, it was engaged in the marketplace and logistics business operations. ContextLogic Inc. was incorporated... in 2010 and is headquartered in Oakland, California. Read more
Pres, CEO & Director
Mr. Frederic Chereau M.B.A.
Pres, CEO & Director
Mr. Frederic Chereau M.B.A.
Headquarters
Oakland, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of LogicBio Therapeutics Inc (LOGC) stood at $ 226 Mln as on 31-Mar-25
The share price of LogicBio Therapeutics Inc (LOGC) is $7.85 (NASDAQ) as of 19-May-2025 16:00 EDT. LogicBio Therapeutics Inc (LOGC) has given a return of 165.38% in the last 3 years.
LogicBio Therapeutics Inc (LOGC) has a market capitalisation of $ 208 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of LogicBio Therapeutics Inc (LOGC) is 1.43 times as on 16-May-2025, a 56% discount to its peers’ median range of 3.23 times.
Since, TTM earnings of LogicBio Therapeutics Inc (LOGC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the LogicBio Therapeutics Inc (LOGC) and enter the required number of quantities and click on buy to purchase the shares of LogicBio Therapeutics Inc (LOGC).
ContextLogic Inc. does not have significant operations. It focuses on identifying, evaluating, and executing strategic opportunities. Previously, it was engaged in the marketplace and logistics business operations. ContextLogic Inc. was incorporated in 2010 and is headquartered in Oakland, California.
The CEO & director of Mr. Frederic Chereau M.B.A.. is LogicBio Therapeutics Inc (LOGC), and CFO & Sr. VP is Mr. Frederic Chereau M.B.A..
There is no promoter pledging in LogicBio Therapeutics Inc (LOGC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
16
|
|
|
2
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,210
|
| LogicBio Therapeutics Inc. (LOGC) | Ratios |
|---|---|
|
Return on equity(%)
|
-13.42
|
|
Operating margin(%)
|
-271.43
|
|
Net Margin(%)
|
-285.71
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of LogicBio Therapeutics Inc (LOGC) was $0 Mln.
$0.05
(
